Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial

R. I. Fisher, W. D. Terry, R. J. Hodes, S. A. Rosenberg, R. Makuch, H. G. Gordon

Research output: Contribution to journalArticlepeer-review

Abstract

The report presents a preliminary analysis of a randomized clinical trial to determine whether the tested forms of immunotherapy or chemotherapy significantly improved the disease-free interval and survival of patients with localized or regional malignant melanoma. Patients with cutaneous Stage I and Stage II melanomas were randomized to receive either no further treatment, BCG alone, BCG plus neuraminidase-treated allogenic cells, or methyl-CCNU. There was a statistically significant improvement in disease-free interval or overall survival rate for any of the treatment arms when compared with the control arm. Prolonged patient followup will be necessary before a final statement can be made regarding the relative effectiveness of these treatment modalities.

Original languageEnglish (US)
Pages (from-to)1267-1277
Number of pages11
JournalUnknown Journal
Volume61
Issue number6
DOIs
StatePublished - Jan 1 1981

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial'. Together they form a unique fingerprint.

Cite this